血清ADA、GPDA及PAB在肝硬化、肝癌患者预后中的意义

Signification of ADA,GPDA and PAB in serum of patients with cirrhosis and liver cancer

目的:探讨肝硬化、肝癌患者血清ADA、GPDA、PAB与患者病情变化及预后的关系。方法:选择2010年1月-2011年5月住院肝病患者(男98例,女73例,年龄35岁～78岁),按不同肝病分为原发性肝癌组,肝癌术后组,肝硬化组,肝良性肿瘤组。正常对照组选择本院健康体检者(100例)。结果:ADA在各肝病组中均有不同程度的升高,以肝硬化组升高最为明显。PAB在各肝病组中同样也以肝硬化组下降最为显著。GPDA在各肝病组中只有肝癌组跟正常对照组有显著性差异,其余组均无统计学意义。结论:ADA、PAB和GPDA的联合检测可作为肝硬化、肝癌的辅助诊断指标,也为肝硬化、肝癌的演变和预后提供监测指标。

Objective：To explore the relation between serum ADA, GPDA and PAB in cirrhosis and liver cancer patients and disease development and prognosis. Methods： Patients with hepatic diseases （98 males and 73 females, aged from 35 to 78 years old） from January 2010 to May 2011 in our hospital were divided into primary liver cancer group, postoperative liver cancer group, cirrhosis group and hepatic benign tumor group. 100 healthy subjects in our hospital were taken as control group. Results： Serum ADA increased in all groups of liver diseases, and it was found most obvious in cirrhosis group. Serum PAB decreased in all groups of liver diseases, and it was found most obvious in cirrhosis group. Serum GPDA had significant difference between pri- mary liver cancer group and the control group, but no statistical significance was found among other groups. Conclusion： Joint test of serum ADA, GPDA and PAB can be used as diagnosis index and monitoring index in progression and prognosis of cirrhosis and liver cancer.